NCT07459660Phase 2Enrolling by invitation

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-03Estimated

Enrollment · participants210Estimated

Source updated2026-08-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-07 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Enrolling by invitation

Check registry source

Posted 2026-04-14 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Psychosis Associated With Alzheimer's Disease

Treatments or interventions studied

ML-007C-MADrug

Primary outcomes · main study measures

measure: To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with AD; description: using the incidence of TEAEs, TE-SAEs, and TEAEs leading to study discontinuation.; timeFrame: From initial dose through end of treatment (up to 52 weeks)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history